Search results for "Rolipram"

showing 7 items of 27 documents

Cyclic AMP elevating agents and nitric oxide modulate angiotensin II-induced leukocyte-endothelial cell interactionsin vivo

2001

Angiotensin (Ang-II) is a key molecule in the development of cardiac ischaemic disorders and displays proinflammatory activity in vivo. Since intracellular cyclic nucleotides elevating agents have proved to be effective modulators of leukocyte recruitment, we have evaluated their effect on Ang-II-induced leukocyte-endothelial cell interactions in vivo using intravital microscopy within the rat mesenteric microcirculation. Pretreatment with iloprost significantly inhibited (1 nM) Ang-II-induced increase in leukocyte rolling flux, adhesion and emigration at 60 min by 96, 92 and 90% respectively, and returned leukocyte rolling velocity to basal levels. Pretreatment with salbutamol or co-superf…

Pharmacologymedicine.medical_specialtyForskolinCell adhesion moleculeLeukocyte RollingBiologyAngiotensin IIEndothelial stem cellchemistry.chemical_compoundEndocrinologychemistryIn vivoInternal medicinemedicineRolipramIntravital microscopymedicine.drugBritish Journal of Pharmacology
researchProduct

Characterization of Membrane-Bound Cyclic Nucleotide Phosphodiesterases from Bovine Aortic Smooth Muscle

1992

This study reports the isolation and characterization of cyclic nucleotide phosphodiesterases (PDEs) associated with membrane fraction in comparison to cytosolic forms from bovine aorta. DEAE-Sephacel chromatography of a solubilized membrane fraction from a homogenate, prepared under isotonic conditions in the presence of protease inhibitors, yielded one major peak of PDE activity that specifically hydrolyzed cAMP and was not stimulated by calmodulin: It appeared to contain two subtypes of PDE. The first subtype belonged to the cyclic GMP (cGMP)-inhibited PDE family, (PDE III): It had an apparent Km value of 0.4 microM and was potently inhibited by cGMP, LY186126, and cilostamide. The secon…

Vascular smooth muscleCalmodulinPhosphodiesterase InhibitorsMuscle Smooth Vascularchemistry.chemical_compoundCytosolCalmodulinCyclic AMPmedicineAnimalsheterocyclic compoundsCyclic GMPRolipramPharmacologyCilostamidebiologyCyclic nucleotide phosphodiesterasePhosphoric Diester HydrolasesHydrolysisCell MembraneBiological membranemusculoskeletal systemenzymes and coenzymes (carbohydrates)Mechanism of actionBiochemistrychemistryEnzyme inhibitorbiology.proteinCattleChromatography Thin Layersense organsmedicine.symptomCardiology and Cardiovascular Medicinecirculatory and respiratory physiologymedicine.drugJournal of Cardiovascular Pharmacology
researchProduct

Phosphodiesterase-4 inhibition improves corticosteroid insensitivity in pulmonary endothelial cells under oxidative stress.

2012

Several clinical studies have shown that smoking in asthmatics and chronic obstructive pulmonary disease patients is closely associated with corticosteroid refractoriness. In this work, we have analyzed glucocorticoid insensitivity in human pulmonary artery endothelial cells (HPAECs) under cigarette smoke extract (CSE) exposure as well as the possible additive effects of the combination therapy with a phosphodiesterase (PDE)-4 inhibitor. Interleukin (IL)-8 was measured in cell supernatants by ELISA. Histone deacetylase (HDAC), histone acetylase (HAT), and intracellular cAMP levels were measured by colorimetric assays and enzyme immunoassay, respectively. PDE4 isotypes and glucocorticoid rec…

medicine.medical_specialtyImmunologyApoptosisDexamethasoneHistone DeacetylasesGlucocorticoid receptorReceptors GlucocorticoidAdrenal Cortex HormonesInternal medicinemedicineCyclic AMPImmunology and AllergyHumansReceptorLungDexamethasoneRolipramCell ProliferationHistone AcetyltransferasesChemistryTumor Necrosis Factor-alphaInterleukin-8InterleukinPhosphodiesteraseEndothelial CellsAparato respiratorioCyclic Nucleotide Phosphodiesterases Type 4Enzyme ActivationOxidative StressEndocrinologyHistone deacetylasePhosphodiesterase 4 InhibitorsPulmonesReactive Oxygen SpeciesRolipramGlucocorticoidmedicine.drugAllergy
researchProduct

Bronchodilator and anti-inflammatory activities of SCA40: studies in human isolated bronchus, human eosinophils, and in the guinea-pig in vivo.

1998

There is currently interest in the use of inhibitors of cyclic nucleotide phosphodiesterases (PDE) as potential anti-asthma agents. In this study we examined the effects of SCA40 (6-bromo-8-methylaminoimidazol-[1,2-a] pyrazine-2-carbonitrile), a preferential inhibitor of PDE 3 also endowed with PDE 4 and 5 inhibitory activities, on isolated bronchus and eosinophil functions and in an animal model of asthma. SCA40 (1 nM-0.1 mM) produced concentration-dependent inhibition of spontaneous and stimulated tone of human isolated bronchus and reached a maximal relaxation similar to that of theophylline (3 mM). The potency (-log EC50 values) of SCA40 against spontaneous tone (6.52 +/- 0.10) was grea…

medicine.medical_specialtyMuscle RelaxationGuinea PigsBronchiIn Vitro Techniqueschemistry.chemical_compoundIn vivoInternal medicinemedicineAnimalsHumansTheophyllineAntigensRolipramPharmacologyLeukotrieneLeukotriene C4Anti-Inflammatory Agents Non-SteroidalImidazolesMuscle SmoothGeneral MedicineEosinophilLeukotriene C4Bronchodilator AgentsEosinophilsmedicine.anatomical_structureEndocrinologychemistryPyrazinesBronchoconstrictionmedicine.symptomBronchial HyperreactivityHistaminemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin in guinea-pigs.

1993

Abstract Rolipram (0·1–1000 μg kg−1, i.v.) reduced the increase in microvascular permeability induced by platelet-activating factor (PAF; 50 ng kg−1, i.v.) at different sites of the guinea-pig airways. Rolipram (1–100μg kg−1, i.v.) inhibited histamine (30μg kg−1, i.v.)-and bradykinin (0·3 μg kg, i.v.)-induced airway microvascular leakage. These effects of rolipram were obtained at doses which inhibit histamine (7–20 μg kg−1 min−1)-induced bronchoconstriction (IC50 = 3 ± 1 μg kg, i.v.) without depressing arterial blood pressure in the guinea-pig. Aminophylline (50 mg kg−1) did not change the effect of PAF. The anti-exudative effect of rolipram is of potential therapeutic value in asthma.

medicine.medical_specialtyPhosphodiesterase InhibitorsGuinea PigsPharmaceutical ScienceBradykininVascular permeabilityBlood PressureBronchiBradykininCapillary Permeabilitychemistry.chemical_compoundInternal medicinemedicineAnimalsDrug InteractionsPlatelet Activating FactorRolipramPharmacologyPlatelet-activating factorMicrocirculationAminophyllinePyrrolidinonesTracheaEndocrinologymedicine.anatomical_structurechemistryBronchoconstrictionAminophyllinemedicine.symptomRolipramHistaminemedicine.drugBlood vesselEvans BlueHistamineThe Journal of pharmacy and pharmacology
researchProduct

ROLIPRAM INHIBITS PAF-INDUCED AIRWAY MICROVASCULAR LEAKAGE IN GUINEA-PIG - A COMPARISON WITH MILRINONE AND THEOPHYLLINE

1992

The effects of 3 phosphodiesterase (PDE) inhibitors, rolipram (PDE IV), milrinone (PDE III) and theophylline (non-selective) on PAF (50 ng kg-1; iv)-induced airway vascular leakage have been evaluated in guinea-pigs. Rolipram (3-300 micrograms kg-1; iv) reduced the increase in permeability induced by PAF at all airway levels whereas milrinone (10-1000 micrograms kg-1; iv) and theophylline (30 mg kg-1; iv) were without effects. The anti-leakage activity of rolipram may be of therapeutic value in asthma.

medicine.medical_specialtyPhosphodiesterase InhibitorsPyridonesGuinea PigsRespiratory SystemVascular permeabilityCapillary Permeabilitychemistry.chemical_compoundTheophyllineInternal medicinemedicineAnimalsPharmacology (medical)TheophyllinePlatelet Activating FactorRolipramPharmacologybiologyCyclic nucleotide phosphodiesterasePlatelet-activating factorbusiness.industryPhosphodiesterasePyrrolidinonesEndocrinologychemistryEnzyme inhibitorbiology.proteinMilrinonebusinessRolipramEvans BlueMilrinonemedicine.drug
researchProduct

Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages

2011

Summary Background Oxidative stress is present in airway diseases such as severe asthma or Chronic Obstructive Pulmonary Disease and contributes to the low response to glucocorticoids through the down-regulation of histone deacetylase (HDAC) activity. Objective To study the effects of the phosphodiesterase (PDE)-3 and 4 inhibitors and their combination vs. glucocorticoids in a model of lipopolysaccharide (LPS)-induced cytokine release in alveolar macrophages under oxidative stress conditions. Methods Differentiated U937 or human alveolar macrophages were stimulated with H2O2 (10–1000 μm) or cigarette smoke extract (CSE, 0–15%) for 4 h before LPS (0.5 μg/mL, 24 h) addition. In other experime…

medicine.medical_specialtymedicine.medical_treatmentImmunologyPhosphodiesterase 3Biologymedicine.disease_causeEndocrinologyCytokineInternal medicinemedicineAlveolar macrophageImmunology and AllergyCytokine secretionDexamethasoneGlucocorticoidOxidative stressRoliprammedicine.drugClinical & Experimental Allergy
researchProduct